Seagen Inc
SGEN
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
1.3% upsideUndervalued by 1.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $43.15 Billion |
|---|---|
| Enterprise Value | $42.84 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.3 |
| Beta | 0.32 |
| Outstanding Shares | 188,135,000 |
Return
| Return on Equity | -29.42% |
|---|---|
| Return on Assets | -20.64% |
| Return on Invested Capital | -30.06% |
Valuation & Multiples
| P/E Ratio | -69.22 |
|---|---|
| PEG | -528.87 |
| Price to Sales | 19.06 |
| Price to Book Ratio | 17.6 |
| Enterprise Value to Revenue | 18.62 |
| Enterprise Value to EBIT | -53.18 |
| Enterprise Value to Net Income | -58 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Seagen Inc
Relevant Senate Committees
Controls taxation, trade, and entitlement spending (e.g., Medicare/Medicaid reimbursement, critical for drug pricing), and corporate tax policy, directly influencing the valuation and revenue of biological product manufacturers.
Allocates discretionary federal spending, with subcommittees determining funding for health-related scientific research (e.g., NIH) and federal healthcare programs, directly impacting the biotech sector.
Directly regulates the FDA (drug approval, manufacturing standards) and NIH (research funding), making it the primary oversight body for biological product manufacturers.
Oversees intellectual property laws (patents are crucial for biotech companies) and antitrust enforcement, both directly impacting a biological product manufacturer's core assets and market structure.